Welcome to our dedicated page for DENTSPLY SIRONA SEC filings (Ticker: XRAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DENTSPLY SIRONA Inc.'s SEC filings document regulatory disclosures for a diversified dental products and technology manufacturer listed on Nasdaq under XRAY. Recent Form 8-K reports furnish operating results, GAAP and non-GAAP reconciliations, outlook commentary, distribution agreements, product and regulatory updates, restructuring actions and capital allocation changes involving dividend policy, debt reduction and share repurchases.
The company's proxy and governance filings cover director elections, board composition, committee assignments, executive compensation and stockholder meeting matters. Other current reports disclose board expansion, director appointments, chief financial officer transition matters, separation arrangements and Regulation FD communications tied to commercial agreements and corporate updates.
Dentsply Sirona (XRAY) reported Q3 2025 results with net sales of $904 million versus $951 million a year ago and an operating loss of $218 million. The quarter included $262 million of goodwill and intangible asset impairments, leading to a net loss of $427 million, or $2.14 per share.
Sales declined in the United States to $291 million from $374 million, while Europe rose to $382 million from $347 million. Segment mix showed Essential Dental Solutions at $357 million and Orthodontic and Implant Solutions at $205 million; Wellspect Healthcare increased to $83 million from $72 million.
Year to date, net sales were $2.719 billion versus $2.888 billion, with $497 million of impairments and a net loss of $452 million. Cash from operating activities was $134 million year to date, ending cash was $363 million. Long‑term debt was $2,017 million and current debt was $378 million. Goodwill decreased to $1,270 million from $1,597 million, and total equity was $1,478 million.
DENTSPLY SIRONA (XRAY) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 under Item 2.02. The company notes this information is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or incorporation by reference unless specifically referenced.
DENTSPLY SIRONA (XRAY) announced a leadership change. On October 31, 2025, the company determined that Matthew E. Garth will no longer serve as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun a search for its next CFO. The filing states Mr. Garth’s departure was not due to any disagreement regarding financial statements, internal controls, or operations.
Effective upon Mr. Garth’s departure, Daniel T. Scavilla, the company’s President and CEO and a director, was appointed as interim principal financial officer for SEC reporting. The company noted no new compensatory arrangements for Mr. Scavilla related to these additional responsibilities, and no related‑party relationships were disclosed.
DENTSPLY SIRONA (XRAY) reported an insider transaction by President & CEO and Director Daniel T. Scavilla. On 10/10/2025, he acquired 223.681 restricted stock units (RSUs) at $0, recorded as dividend equivalents on existing RSUs. Following this, his beneficial ownership stands at 17,698.73 shares, held directly.
The filing notes these RSU dividends carry the same vesting schedule as the underlying awards, and each RSU converts to one share of common stock upon vesting.
DENTSPLY SIRONA (XRAY) filed a Form 4 for an executive equity accrual. On 10/10/2025, the SVP, Chief Supply Chain Office reported 972.381 shares of common stock acquired at $0, credited as dividends on restricted stock units that vest with the underlying awards and convert 1:1 into common stock.
The filing also reports 40.5116 phantom stock units under the SERP acquired at $11.98, each economically equivalent to one share and payable in stock upon termination of employment. Following these entries, direct ownership stands at 124,187.521 common shares and 3,072.9326 phantom stock units.
DENTSPLY SIRONA (XRAY) reported an insider transaction by SVP, CHRO Andrea Frohning. On 10/10/2025, she acquired 357.053 shares of common stock at $0, representing dividend equivalents on previously awarded RSUs that vest with their underlying awards; each RSU converts to common stock on a 1:1 basis.
She also acquired 22.893 shares of phantom stock under the Supplemental Executive Retirement Plan at a $11.98 derivative security price; phantom stock is economically equivalent to common stock and becomes payable in common stock upon termination of employment. Following these transactions, she beneficially owned 33,609.865 shares of common stock directly and 1,736.5455 phantom stock units directly.
DENTSPLY SIRONA (XRAY) reported an insider transaction by its EVP & CFO. On 10/10/2025, the officer acquired 556.226 shares (Transaction Code A) at $0. A footnote explains these represent dividend equivalents on previously granted RSUs, issued as additional RSUs that vest on the same schedule as the underlying awards and convert to common stock on a 1:1 basis.
After this transaction, the reporting person beneficially owned 44,011.347 shares, held directly.
DENTSPLY SIRONA (XRAY) director Brian T. Gladden reported an automatic credit of 286.094 additional RSUs on 10/10/2025 at $0, reflecting dividend equivalents on prior RSU awards. Each RSU converts 1:1 into common stock and follows the same vesting schedule as the underlying awards. After this entry, his beneficial ownership stood at 28,726.563 shares, held directly.
DENTSPLY SIRONA (XRAY) reported an insider equity change by director Betsy D. Holden. On 10/10/2025, the filing lists Common Stock acquired under code “A” totaling 646.937 at $0. The footnote explains these reflect dividend equivalents on restricted stock units (RSUs) credited as additional RSUs, which vest on the same schedule as the underlying awards, and each RSU converts to common stock on a 1:1 basis. Following the transaction, Holden beneficially owned 53,902.896 shares, held directly.
DENTSPLY SIRONA (XRAY) director filed a Form 4 reporting RSU dividend equivalents. On 10/10/2025, the reporting person acquired 286.094 restricted stock units as dividends on existing RSUs at a price of $0. Following this transaction, beneficial ownership stands at 40,897.4765 shares, held directly.
The company states these are dividends on RSUs awarded to the reporting person, delivered as additional RSUs that carry the same vesting terms as the underlying awards. Each RSU converts to common stock on a 1:1 basis, and the dividend RSUs vest simultaneously with the related RSUs.